Skip to main content
. Author manuscript; available in PMC: 2021 Apr 2.
Published in final edited form as: Semin Arthritis Rheum. 2020 Jul 23;50(5):988–995. doi: 10.1016/j.semarthrit.2020.07.008

Figure 2:

Figure 2:

Differences in the use of bDMARDs by racial/ethnic groups among SSDI beneficiaries with RA who were disabled and younger than 65 years.

Percentage of all patients among each racial/ethnic group who used SQ or IV bDMARDs, by year.

Adjusted for age, sex, United States region, heart failure, chronic obstructive pulmonary disease, area deprivation index, fibromyalgia, diabetes, diabetes complications, mental illnesses, transient ischemic attack, stroke or myocardial infarction, and peripheral vascular disease.

Mental illness was defined as any of the following conditions: anxiety, depression, bipolar disorder, multiple personality disorder or schizophrenia.

*Statistically significant vs. the percentage for White patients